Related Experiment Video

Updated: Sep 10, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

792

Novel biomarkers of the Framingham risk score in patients with depression: A cross-sectional study

Li-Na Zhou1, Yan Mao2, Bai-Jia Li3

  • 1Department of Psychiatry, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China. zhoulinapsy@xjtu.edu.cn.

World Journal of Psychiatry
|August 21, 2025
PubMed

Insights

Patients with depression have a higher risk of coronary heart disease (CHD). Novel biomarkers like triglyceride and uric acid levels, along with illness duration and family history, can help predict this increased CHD risk.

Area of Science:

  • Cardiology
  • Psychiatry
  • Biomarkers

Background:

  • Coronary heart disease (CHD) prevalence is elevated in individuals with depression.
  • Novel biomarkers for CHD risk assessment are often altered in patients with depression.

Purpose of the Study:

  • To investigate the association between novel cardiovascular biomarkers and increased CHD risk in patients diagnosed with depression.

Main Methods:

  • Recruited 164 patients with depression and 279 healthy controls for comparison.
  • Assessed CHD risk using the Framingham CHD risk score.
  • Analyzed novel cardiovascular biomarkers and clinical data in relation to CHD risk.

Main Results:

  • Patients with depression exhibited a 5.3% higher CHD risk and altered biomarker levels (e.g., lower thyroid stimulating hormone, albumin, total bilirubin, cholesterol; higher triglyceride and uric acid).
  • Illness duration, family history of depression, serum triglyceride, and uric acid levels significantly correlated with CHD risk in the depression group.

Conclusions:

  • Patients with depression face higher CHD risk, influenced by illness duration, family history, triglyceride, and uric acid levels.
  • Elevated CHD risk in depression is linked to physiological changes and potential genetic susceptibility.
Abstract

Keywords:
Cardiovascular biomarkersCardiovascular riskCoronary heart diseaseDepressionFramingham risk score

More Related Videos

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

22.7K
Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression08:42

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression

Published on: May 19, 2015

10.8K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
213
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
344
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
212
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
166
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
332